A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Cobimetinib (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 20 Jan 2018 Results (n=84) assessing safety and pharmacology of atezolizumab administered with cobimetinib in patients with locally advanced or metastatic solid tumors, were presented at the 2018 Gastrointestinal Cancers Symposium.
    • 20 Jan 2018 According to an Exelixis media release, as of the September 4, 2017 data cut-off, a total of 84 patients with metastatic CRC from both stages of the trial were evaluable for safety and clinical activity.
    • 20 Jan 2018 Results (n = 84) presented in an Exelixis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top